<DOC>
	<DOCNO>NCT03099356</DOCNO>
	<brief_summary>This study non-randomized pilot trial use Cyclophosphamide Sirolimus treatment metastatic differentiate thyroid cancer . Patients treat Sirolimus 4 mg , PO , day 1-28 well Cyclophosphamide 100 mg , PO , day 1-5 15-19 . Cycle length 28 day . Patients monitor closely toxicity undergo image evaluate efficacy every 2 cycle .</brief_summary>
	<brief_title>Cyclophosphamide Sirolimus Treatment Metastatic , RAI-refractory , Differentiated Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically document differentiated thyroid cancer without metastasis , amenable curative treatment ; patient document refusal curative treatment Measurable disease ( &gt; 10 mm ) progression disease base RECIST criterion . Previously irradiated tumor lesion consider measurable unless progress since radiation . Previous failure Iodine131 ( 131I ) therapy candidate receive 131I assessed treat physician . Age ≥ 18 year ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Life expectance ≥ 12 week 131I therapy allow within 24 week entry ( 4 week negative posttreatment scan ) Adequate organ marrow function Women childbearing potential must negative serum urine pregnancy test within 3 day prior treatment Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment Willingness ability comply schedule visit , treatment plan , include willingness take study medication , laboratory test , study procedure Inability obtain Foundation One test archival tissue , , lack previous Next Generation Sequencing Chemotherapy , tyrosine kinase inhibitor , radiation therapy within 4 week Prior experimental therapy within 4 week plan start trial 131I therapy within 24 week entry ( 4 week negative posttreatment scan ) Previous treatment mTOR inhibitor Patients currently receive treatment strong inhibitor inducer CYP3A4 Pglycoprotein discontinue least one week prior start treatment Cyclophosphamide Sirolimus Impairment GI ( gastrointestinal ) function GI disease may significantly alter absorption study medication ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) include dependence GTube administration medication . A serious uncontrolled medical disorder active infection would impair ability receive study treatment Patients know sensitivity either cyclophosphamide and/or sirolimus Patients know urinary outflow obstruction Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol Patients ( male female ) procreative potential willing able use adequate contraception practice abstinence Women pregnant breastfeeding Patients reside prison</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>